2023
Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
Sipra Q, Bin Riaz I, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA). Journal Of Clinical Oncology 2023, 41: 694-694. DOI: 10.1200/jco.2023.41.6_suppl.694.Peer-Reviewed Original ResearchRenal cell carcinomaDisease-free survivalAdjuvant immunotherapyBaseline riskCell carcinomaTreatment optionsImproved disease-free survivalLocalized Renal Cell CarcinomaRisk categoriesAdjuvant treatment optionsAbsolute risk differenceUnique treatment optionRisk stratification systemMixed treatment comparisonSignificant differencesRelative effect estimatesEvidence synthesis frameworkAdjuvant pembrolizumabNivolumab-ipilimumabOverall survivalTreatment landscapeAbsolute benefitPreferred treatmentRecent trialsDisease progression
2022
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
Riaz I, Sipra Q, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A, Murad M. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews In Oncology/Hematology 2022, 175: 103706. PMID: 35537621, DOI: 10.1016/j.critrevonc.2022.103706.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAbsolute benefitCell carcinomaTreatment-related grade 3Adjuvant treatment optionsHigher adverse eventsDisease-free survivalRisk-adapted strategyDelays disease progressionLarger tumor sizeEvidence synthesis frameworkAdjuvant therapyAdjuvant treatmentOverall survivalAdverse eventsNodal positivityLeibovich scoreTumor sizeTreatment optionsDisease progressionRisk groupsGrade 3Current evidenceComparative effectivenessSystematic review
2021
Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz I, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi S, Warner J, Murad M, Kohli M. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clinical Cancer Informatics 2021, 5: 588-599. PMID: 34043431, DOI: 10.1200/cci.21.00035.Peer-Reviewed Original ResearchConceptsAdjuvant tyrosine kinase inhibitorsTyrosine kinase inhibitorsRenal cell carcinomaTrial sequential analysisCell carcinomaTKI monotherapyClinical trialsHigh-risk renal cell carcinomaMultiple large clinical trialsKinase inhibitorsLiving Systematic ReviewRandomized phase 2High-risk patientsCertainty of evidenceLarge clinical trialsKey clinical outcomesAdverse event riskLack of benefitOS benefitPROTECT trialGRADE approachClinical outcomesRandomized trialsCancer recurrenceSTUDY SELECTION